Company Profile
Curie Capital, founded in 2018 and headquartered in Amsterdam, Netherlands, is a venture capital firm specializing in early-stage investments within the life sciences sector. The firm focuses on Seed and Series A rounds, targeting innovative biotechnology, pharmaceutical, and medical technology companies, particularly those developing therapeutics, diagnostics, or class IIb and III medical devices.
Curie Capital not only provides capital but also strategic support, leveraging its extensive network and experience to help build successful companies. Operating primarily from its current fund, Curie Capital 3, the firm complies with RVO seed capital regulations, investing exclusively in companies headquartered in the Netherlands that have not raised more than €3.5 million in equity or convertible loans.
With the anticipated launch of Curie Capital 4 in 2025, the firm plans to broaden its investment scope to include high-impact life sciences companies across Europe, expanding beyond its Dutch-centric focus. The Curie Capital team consists of life science experts and business analysts who actively guide portfolio companies through research and development phases. The firm typically acts as a lead investor and syndicates investments with experienced co-investors.
Notable portfolio companies include TargED Biopharmaceuticals, Citryll, and Avidicure, reflecting Curie Capital’s commitment to advancing cutting-edge medical innovations.
News & Signals (0)
No linked news activity found for this company.